Content
All Posts > Content under Healthcare
Exactly What The Bulls Wanted
Article By:
Geoff Bysshe
Read
Wednesday, August 30, 2017 9:39 PM EDT
All but one of the 14 major market sectors was up today. The top 3 sectors in our summary table were 3 of the 4 biggest movers. This is good news for the bull market.
In this article: IBB, IYT, SMH, VXX, XLK, XLV Also: QQQ, DIA, EWW, FXI, GDX, GLD, IWM, IYR, KRE, SLV, SPY, TAN, TLT, UNG, USO, UUP, XLU, XRT
M&A Theme Continues To Boost Biotech Stocks
Article By:
Rod Raynovich
Read
Wednesday, August 30, 2017 9:30 PM EDT
The prospect of more M&A boosts biotech stocks for a third day this week. The large cap based IBB was up 1.87% today and 6.48% over five days to $323.76 approaching its YTD high of $327.34.
AstraZeneca And Takeda Ink Deal To Develop Parkinson's Drug
Article By:
Zacks Investment Research
Read
Wednesday, August 30, 2017 3:10 PM EDT
AstraZeneca PLC and Takeda Pharmaceutical Company Limited, a Japanese pharma company, have entered into an agreement to jointly develop and commercialize preclinical candidate MEDI1341.
Biotech Digest – URGN Receives Fast Track Designation, MDVX Receives Australian Approval, AZN Inks A New Deal
Article By:
KKD Healthcare Analytics
Read
Wednesday, August 30, 2017 12:45 PM EDT
UroGen Pharma announced that the FDA has designated its MitoGel for Fast Track review for the treatment of patients with low-grade upper urinary tract urothelial carcinoma. AstraZeneca inked a new deal with Takeda Pharmaceutical.
Three Top Healthcare Mutual Funds For Bipartisan Reform
Article By:
Zacks Investment Research
Read
Tuesday, August 29, 2017 9:35 PM EDT
Even with the uncertainty of the Affordable Care Act’s (ACA) future, the Healthcare sector has been one of the top performing segments in 2017. I have selected three top mutual funds for bipartisan reform.
Biotech ETFs Soar On Gilead-Kite Deal
Article By:
Zacks Investment Research
Read
Tuesday, August 29, 2017 2:56 PM EDT
Through ETF ways, investors get to play the overall evolvement of the biotech space and certain downbeat VGM scores of GILD and KITE would not come in the way of investors’ optimism.
Nuvectra Corporation - Sold
Article By:
Jim Van Meerten
Read
Tuesday, August 29, 2017 2:26 PM EDT
This morning I deleted Nevectra from my portfolio at 10.55. It is not adding any value to the portfolio.
In this article: NVTR
Anthera's Blisibimod Positive In Phase II Extension Study
Article By:
Zacks Investment Research
Read
Tuesday, August 29, 2017 1:43 PM EDT
Anthera Pharmaceuticals, Inc. announced positive top-line data from the extension of a phase II BRIGHT-SC study, evaluating key pipeline candidate, blisibimod for treatment of patients with IgA nephropathy (IgAN).
With $12B Deal, Kite Pharma Continues To Soar
Grow Generation Inks Strategic Partnership With Lumigrow
Article By:
Technical420
Read
Tuesday, August 29, 2017 11:41 AM EDT
GrowGeneration Corp., one of the largest specialty retail hydroponic and organic gardening stores, announced today they have signed a strategic partnership with LumiGrow Inc., a smart horticultural lighting company.
In this article: GRWG
Talking With NuLife's CEO About Transplants And Technology
Article By:
Trevor Lowenthal
Read
Tuesday, August 29, 2017 10:38 AM EDT
NuLife is a very early stage, precommercialization company exploring alternatives to transplants, initially for kidney patients.
In this article: NULF
Pfizer Presents Encouraging Eliquis Results In NVAF Patients
Article By:
Zacks Investment Research
Read
Tuesday, August 29, 2017 7:57 AM EDT
Pfizer Inc. and partner Bristol-Myers Squibb Company presented findings from a phase IV study on Eliquis, which demonstrated the oral anticoagulation’s potential in achieving and maintaining normal heart rhythm (cardioversion).